SYNTHESIS AND BIOLOGICAL EVALUATION OF SOME NOVEL METHYLPYRIMIDINE DERIVATIVES AS AN ANTIDIABETIC AND ANTIHYPERLIPIDEMIC AGENTS

Diabetes and hyperlipidemia become a major risk factor for cardiovascular diseases in the world. Hyperlipidemia is a relatively common problem in patients with poorly controlled diabetes. In searching for a new class of antidiabetic and antihyperlipidemic agents, many compounds with pyridine moiety have been found to possess good activity against diabetes and hyperlipidemia. The present study was carried out to synthesize, characterize, and screening of methyl pyrimidine derivatives for antidiabetic and antihyperlipidemic activity. A novel series of 2-amino-4-(substituted phenylamino)-6-methylpyrimidine derivatives have been synthesized from Guanidine hydrochloride. Synthesized compounds were characterized by IR, MASS, ¹H-NMR, and C NMR spectroscopy. Synthesized compounds were screened for antidiabetic and antihyperlipidemic activity in Swiss albino mice. The blood sample was collected and used to determine serum glucose, triglyceride, LDL (low-density lipoprotein), HDL (high-density lipoprotein), and total cholesterol level in mice. Among the synthesized derivatives, 2-amino-4-(4-methoxyphenylamino)-6-methylpyrimidine and 2-amino-4-(4-bromophenylamino)-6-methylpyrimidine shows good antidiabetic and antihyperlipidemic activity which was comparable to the standard drug, and it can be useful for the further clinical studies.